Y-mAbs Therapeutics
Social media
Y-mAbs Therapeutics Logo
About Y-mAbs Therapeutics
Y-mAbs Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of novel antibody-based and radioimmunotherapy treatments for cancer. Its lead product, DANYELZA, is approved for pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also advancing a pipeline of antibody therapeutics, including candidates for osteosarcoma, GD2-positive solid tumors, and central nervous system metastases. Y-mAbs Therapeutics was founded in 2015 and is headquartered in New York, serving patients in the United States and internationally.
Address
230 Park Avenue, Suite 3350
New York, 10169
United States
Year founded
2015
Number of employees
100-200
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
